European Commission approves RYBREVANT in combination with chemotherapy for advanced EGFR-mutated non-small cell lung ...
The European Commission (EC) has approved a Type II extension of indication for Janssen-Cilag International NV’s (a Johnson & Johnson company) RYBREVANT (amivantamab) in combination with chemotherapy (carboplatin and pemetrexed), for the treatment of …